Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ritter Pharmaceuticals
Los Angeles, California, United Statesritterpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ritter’s lead asset RP-G28 completed Phase 2b/3 trials for lactose intolerance. The company demonstrated that RP-G28 could beneficially modulate the gut microbiome to improve tolerance to lactose-containing foods. No FDA-approved product resulted prior to acquisition; efforts to monetize RP-G28 continued post-merger under a Contingent Value Right agreement.
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- Small moleculesMicrobiome modulatorsNutritional supplements
- Industry
- Biotech
02
Partnerships
Medpace selected as CRO for pivotal Phase III trial of RP-G28Sekisui Diagnostics distributed diagnostic products post-merger via parent company’s business lines.
Beyond the preview
Go deeper on Ritter Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ritter Pharmaceuticals.